The Association for Accessible Medicines has urged US lawmakers to take action on originator tactics used to “game the system”, including ‘product hopping’ and biosimilar patent thickets used to deter competition.
Testifying before a House of Representatives subcommittee on consumer protection and commerce, AAM senior vice-president Jeffrey Francer said that “current market realities and anti-competitive tactics – combined with misguided
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?